In addition, routine immunohistochemistry (IHC) tumour markers, i.e. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), as well as grade and Ki67, are independent predictors of breast cancer death and have therefore together with TNM been guiding treatment decisions in the past decades [5–7]. This evidence concerns the gene MKI67 and neoplasm.